Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
120 hedge funds and large institutions have $249M invested in Provention Bio, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 52 increasing their positions, 24 reducing their positions, and 15 closing their positions.
239% more call options, than puts
Call options by funds: $8.85M | Put options by funds: $2.61M
117% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 24
93% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 15
13% more funds holding
Funds holding: 106 → 120 (+14)
34% less capital invested
Capital invested by funds: $378M → $249M (-$129M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$10.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.59M |
| 3 |
BlackRock
New York
|
+$7.57M |
| 4 |
Two Sigma Advisers
New York
|
+$4.63M |
| 5 |
Goldman Sachs
New York
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$19.3M |
| 2 |
DCM
DG Capital Management
New York
|
-$7.51M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$5.8M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$4.6M |
| 5 |
6CM
683 Capital Management
New York
|
-$3.23M |
PRVB Hedge Fund Activity: Q1 2021 in Review
120 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q1 2021, worth a combined $249M — down 34% from $378M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PRVB positions and 15 closed out — a net gain of 14 holders — while 52 added to existing stakes and 24 trimmed.
The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $10.6M. The largest seller was Perceptive Advisors, cutting an estimated $19.3M.
- 120 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q1 2021, up from 106 in Q4 2020.
- Funds reported $249M of Provention Bio, Inc. Common Stock stock for Q1 2021, down 34% quarter-over-quarter.
- 29 funds opened new Provention Bio, Inc. Common Stock positions in Q1 2021 and 15 closed out, a net change of +14 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q1 2021 was Gilder Gagnon Howe & Co, an estimated $10.6M added.
- The largest Provention Bio, Inc. Common Stock seller in Q1 2021 was Perceptive Advisors, an estimated $19.3M sold.
Based on aggregated 13F filings for Q1 2021.